Literature DB >> 8241857

Injection immunotherapy. British Society for Allergy and Clinical Immunology Working Party.

A J Frew1.   

Abstract

A working party of the British Society for Allergy and Clinical Immunology has reviewed the role of specific allergen immunotherapy in the treatment of allergic disease and produced a position statement summarising the available evidence for efficacy and safety. The working party recommends specific allergen immunotherapy for treating summer hay fever uncontrolled by conventional medication and for wasp and bee venom hypersensitivity. It is not recommended for asthma or for allergic rhinitis due to other allergens. For the recommended indications the risk:benefit ratio is acceptable provided patients are carefully selected; in particular, patients with asthma should be excluded as they are especially vulnerable to adverse reactions. Injections should be given only by doctors experiences in this form of treatment in a clinic where full resuscitative facilities are immediately available. Provided patients remain symptom free a 60 minute observation period after injection is sufficient to detect all serious adverse reactions.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8241857      PMCID: PMC1679037          DOI: 10.1136/bmj.307.6909.919

Source DB:  PubMed          Journal:  BMJ        ISSN: 0959-8138


  22 in total

1.  Immunotherapy of pollinosis in children: investigation of the immunologic basis of clinical improvement.

Authors:  N Sadan; M B Rhyne; E D Mellits; E O Goldstein; D A Levy; L M Lichtenstein
Journal:  N Engl J Med       Date:  1969-03-20       Impact factor: 91.245

2.  Allergy to insect stings: a review.

Authors:  P W Ewan
Journal:  J R Soc Med       Date:  1985-03       Impact factor: 5.344

3.  Immunotherapy in bee sting hypersensitivity. Bee venom versus wholebody extract.

Authors:  U Müller; U Thurnheer; R Patrizzi; J Spiess; R Hoigné
Journal:  Allergy       Date:  1979-12       Impact factor: 13.146

4.  Grass pollen immunotherapy: a single year double-blind, placebo-controlled study in patients with grass pollen-induced asthma and rhinitis.

Authors:  C Ortolani; E Pastorello; R B Moss; Y P Hsu; M Restuccia; G Joppolo; A Miadonna; U Cornelli; G Halpern; C Zanussi
Journal:  J Allergy Clin Immunol       Date:  1984-02       Impact factor: 10.793

5.  Venom immunotherapy: comparison of "rush" vs "conventional" schedules.

Authors:  S A Gillman; L H Cummins; P P Kozak; D R Hoffman
Journal:  Ann Allergy       Date:  1980-12

6.  Immunotherapy with a standardized Dermatophagoides pteronyssinus extract. I. In vivo and in vitro parameters after a short course of treatment.

Authors:  J Bousquet; P Calvayrac; B Guérin; A Hejjaoui; H Dhivert; B Hewitt; F B Michel
Journal:  J Allergy Clin Immunol       Date:  1985-11       Impact factor: 10.793

7.  Hyposensitization with a tyrosine adsorbed extract of Dermatophagoides pteronyssinus in adults with perennial rhinitis. A controlled clinical trial.

Authors:  A D Blainey; M J Phillips; S Ollier; R J Davies
Journal:  Allergy       Date:  1984-10       Impact factor: 13.146

8.  Measurement of IgG-blocking antibodies: development and application of a radioimmunoassay.

Authors:  A K Sobotka; M D Valentine; K Ishizaka; L M Lichtenstein
Journal:  J Immunol       Date:  1976-07       Impact factor: 5.422

9.  Controlled trial of hyposensitisation to Dermatophagoides pteronyssinus in children with asthma.

Authors:  J O Warner; J F Price; J F Soothill; E N Hey
Journal:  Lancet       Date:  1978-10-28       Impact factor: 79.321

10.  Clinical relevance of the venom-specific immunoglobulin G antibody level during immunotherapy.

Authors:  D B Golden; D A Meyers; A Kagey-Sobotka; M D Valentine; L M Lichtenstein
Journal:  J Allergy Clin Immunol       Date:  1982-06       Impact factor: 10.793

View more
  7 in total

Review 1.  Allergen injection immunotherapy for seasonal allergic rhinitis.

Authors:  M A Calderon; B Alves; M Jacobson; B Hurwitz; A Sheikh; S Durham
Journal:  Cochrane Database Syst Rev       Date:  2007-01-24

Review 2.  Immunotherapy in asthma.

Authors:  J A Douglass; F C Thien; R E O'Hehir
Journal:  Thorax       Date:  1997-08       Impact factor: 9.139

3.  Injection immunotherapy.

Authors:  L J Youlten
Journal:  BMJ       Date:  1994-01-15

Review 4.  Mold allergens in respiratory allergy: from structure to therapy.

Authors:  Teresa E Twaroch; Mirela Curin; Rudolf Valenta; Ines Swoboda
Journal:  Allergy Asthma Immunol Res       Date:  2015-03-11       Impact factor: 5.764

Review 5.  Venom Immunotherapy and Aeroallergen Immunotherapy: How Do Their Outcomes Differ?

Authors:  Cristoforo Incorvaia; Erminia Ridolo; Marina Mauro; Francesco Pucciarini; Enrico Heffler; Giorgio Walter Canonica
Journal:  Front Allergy       Date:  2022-02-16

6.  A limited CpG-containing oligodeoxynucleotide therapy regimen induces sustained suppression of allergic airway inflammation in mice.

Authors:  John D Campbell; Sariah A Kell; Heather M Kozy; Jeremy A Lum; Rosemary Sweetwood; Mabel Chu; Cameron R Cunningham; Hugh Salamon; Clare M Lloyd; Robert L Coffman; Edith M Hessel
Journal:  Thorax       Date:  2014-01-24       Impact factor: 9.139

7.  BSACI guidelines for the management of allergic and non-allergic rhinitis.

Authors:  G K Scadding; S R Durham; R Mirakian; N S Jones; S C Leech; S Farooque; D Ryan; S M Walker; A T Clark; T A Dixon; S R A Jolles; N Siddique; P Cullinan; P H Howarth; S M Nasser
Journal:  Clin Exp Allergy       Date:  2008-01       Impact factor: 5.018

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.